Value through InnovationFebruary 04 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10
02.03.2016

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents

01.27.2016

Boehringer Ingelheim’s Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer

01.25.2016

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

12.21.2015

Boehringer Ingelheim’s third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer

12.16.2015

FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment

12.14.2015

First Multinational Study Initiated to Evaluate OFEV® (nintedanib) with Add-on of pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis

12.08.2015

New Phase III Study of Nintedanib in People with Systemic Sclerosis and Lung Fibrosis Launched

12.02.2015

Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

11.23.2015

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Prophylaxis of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) after Hip Replacement Surgery

11.18.2015

Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundation’s Corporate Equality Index

back 1 2 3 4 5 6 7 8 9 10